Management of Generalized Anxiety Disorder in Primary Care: Identifying the Challenges and Unmet Needs
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Generalized anxiety disorder (GAD) is one of the most common psychiatric disorders in primary care, although it is often underrecognized and undertreated. GAD is chronic, disabling, and associated with other health problems. Treatment response is often unsatisfactory, but the clinical evidence base for new treatments has expanded substantially in the past decade and suggests a growing range of options for reducing the burden of GAD. The objective of this article was to review current literature on GAD and its management to provide an overview of the clinical importance of GAD in primary care and available treatments. DATA SOURCES: Recent studies (ie, over the past decade) on the epidemiology and treatment of GAD were identified by searching Medline using the term generalized anxiety disorder only and in combination with the terms epidemiology and treatment and for each drug class (benzodiazepines, azapirones, antidepressants, antihistamines, alpha-2-delta ligands, and antipsychotics) and for named drugs (buspirone, venlafaxine, duloxetine, fluoxetine, escitalopram, olanzapine, paroxetine, pregabalin, quetiapine, and risperidone in addition to psychological therapies and cognitive-behavioral therapy. The literature search was conducted in August 2008 for the period 1987-2009. STUDY SELECTION: Studies were included if judged to be relevant to a review of the epidemiology and management of GAD. Articles were excluded if they were not written in English or were published more than 10 years before the literature search was conducted. A few older studies were included for which more recent research evidence was not available. Recent national and international guidelines for the management of GAD were also reviewed. DATA EXTRACTION/SYNTHESIS: Most currently available interventions have similar overall efficacy, and treatment choices should reflect the situation of individual patients. Important unmet needs exist for treatments (1) that work rapidly, with (2) broad spectrum benefits, (3) that can improve rates of remission and well-being, (4) are devoid of risk for withdrawal symptoms, and (5) have few if any adverse interactions with other drugs. Additional needs include (6) safer drugs for the elderly, (7) safe and effective drugs for children with GAD, (8) further evaluation of psychotherapy, and (9) understanding the appropriate circumstances for, and optimal choices of, drug combination. CONCLUSION: While the development of novel treatments evolves, current management approaches can focus on improving identification and defining optimal use of available therapies for GAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967
McWilliams, L. A., Cox, B. J., & Enns, M. W. (2003) · Pain · doi:10.1016/s0304-3959(03)00301-4 · Cited by 951
Conway, K. P., Compton, W., Stinson, F. S., & Grant, B. F. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0211 · Cited by 934
Sirey, J. A., Bruce, M. L., Alexopoulos, G. S., Perlick, D. A., Friedman, S. J., & Meyers, B. S. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.12.1615 · Cited by 796
Generalized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733
Anxiety disorders and comorbid medical illness
Roy-Byrne, P. P., Davidson, K. W., Kessler, R. C., Asmundson, G. J. G., Goodwin, R. D., Kubzansky, L., Lydiard, R. B., Massie, M. J., Katon, W., Laden, S. K., et al. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.12.006 · Cited by 668
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Fergusson, D., Doucette, S., Glass, K. C., Shapiro, S., Healy, D., Hebert, P., & Hutton, B. (2005) · BMJ · doi:10.1136/bmj.330.7488.396 · Cited by 510
Well-Being Therapy of Generalized Anxiety Disorder
Fava, G. A., Ruini, C., Rafanelli, C., Finos, L., Salmaso, L., Mangelli, L., & Sirigatti, S. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000082023 · Cited by 344
Use of benzodiazepines in anxiety disorders
Wood, A. J. J., Shader, R. I., & Greenblatt, D. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305133281907 · Cited by 341
Thase, M. E. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1002 · Cited by 331
Psychological therapies for generalised anxiety disorder
Hunot, V., Churchill, R., Teixeira, V., & Silva de Lima, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001848.pub4 · Cited by 315
Associations between anxiety disorders and physical illness
H�rter, M. C., Conway, K. P., & Merikangas, K. R. (2003) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-003-0449-y · Cited by 297
The ESEMeD/MHEDEA 2000 investigators, Alonso, J., Angermeyer, M. C., Bernert, S., Bruffaerts, R., Brugha, T. S., Bryson, H., de Girolamo, G., de Graaf, R., Demyttenaere, K., et al. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0047.2004.00328.x · Cited by 242
Hu, X. H., Bull, S. A., Hunkeler, E. M., Ming, E., Lee, J. Y., Fireman, B., & Markson, L. E. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0712 · Cited by 235
Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder
Öst, L.-G., & Breitholtz, E. (2000) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(99)00095-9 · Cited by 229
Brambilla, P., Cipriani, A., Hotopf, M., & Barbui, C. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-837806 · Cited by 181
Allgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175
Gibbons, R. D., Brown, C. H., Hur, K., Marcus, S. M., Bhaumik, D. K., & Mann, J. J. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1044 · Cited by 167
Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management
Schweizer, E., & Rickels, K. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb05973.x · Cited by 163
Ruscio, A. M., Chiu, W. T., Roy-Byrne, P., Stang, P. E., Stein, D. J., Wittchen, H.-U., & Kessler, R. C. (2007) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2006.10.004 · Cited by 145
Azapirones for generalized anxiety disorder
Chessick, C. A., Allen, M. H., Thase, M. E., Batista Miralha da Cunha, A. A., Kapczinski, F., Silva de Lima, M., & dos Santos Souza, J. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006115 · Cited by 144
Williams, L. J., Henry, M. J., Berk, M., Dodd, S., Jacka, F. N., Kotowicz, M. A., Nicholson, G. C., & Pasco, J. A. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b3bb · Cited by 117
IS THERE A RATIONALE FOR PRESCRIPTION OF BENZODIAZEPINES IN THE ELDERLY? REVIEW OF THE LITERATURE
Petrovic, M., Mariman, A., Warie, H., Afschrift, M., & Pevernagie, D. (2003) · Acta Clinica Belgica · doi:10.1179/acb.2003.58.1.004 · Cited by 76
Rodriguez, B. F., Weisberg, R. B., Pagano, M. E., Machan, J. T., Culpepper, L., & Keller, M. B. (2004) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2003.09.005 · Cited by 64
Psychopharmacologic Treatment of Generalized Anxiety Disorder and the Risk of Major Depression
Goodwin, R. D., & Gorman, J. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1935 · Cited by 49
Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam
Beekman (1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1099-1166(1998100)13:10 · Cited by 2
Cited by
Rebar, A. L., Stanton, R., Geard, D., Short, C., Duncan, M. J., & Vandelanotte, C. (2015) · Health Psychology Review · doi:10.1080/17437199.2015.1022901 · Cited by 1,323
Newton, J. N., Briggs, A. D. M., Murray, C. J. L., Dicker, D., Foreman, K. J., Wang, H., Naghavi, M., Forouzanfar, M. H., Ohno, S. L., Barber, R. M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00195-6 · Cited by 345
Oxytocin׳s role in anxiety: A critical appraisal
MacDonald, K., & Feifel, D. (2014) · Brain Research · doi:10.1016/j.brainres.2014.01.025 · Cited by 139
Agomelatine for the treatment of generalized anxiety disorder
Buoli, M., Grassi, S., Serati, M., & Altamura, A. C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359257 · Cited by 61
Vera, M., Obén, A., Juarbe, D., Hernández, N., & Pérez-Pedrogo, C. (2021) · Journal of Behavioral and Cognitive Therapy · doi:10.1016/j.jbct.2020.11.007 · Cited by 8
Metadata
- Authors
- Davidson, J. R. T., Feltner, D. E., & Dugar, A.
- Venue
- The Primary Care Companion to The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-03-04
- Volume
- 12
- Issue
- 2
- ISSN
- 1523-5998 (ISSN-L)
- 1555-211X
- OpenAlex
- W2032925567
- Cited by
- 54
- References
- 30
- FWCI
- 7.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.